Literature DB >> 30076177

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Stephanie Sasse1, Katharina Reddemann2, Arjan Diepstra3, Ilske Oschlies2, Antje Schnitter2, Sven Borchmann4,5,6, Andreas Engert4, Peter Borchmann4, Wolfram Klapper2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30076177      PMCID: PMC6312019          DOI: 10.3324/haematol.2018.196279

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Authors:  Jesse M Zaretsky; Angel Garcia-Diaz; Daniel S Shin; Helena Escuin-Ordinas; Willy Hugo; Siwen Hu-Lieskovan; Davis Y Torrejon; Gabriel Abril-Rodriguez; Salemiz Sandoval; Lucas Barthly; Justin Saco; Blanca Homet Moreno; Riccardo Mezzadra; Bartosz Chmielowski; Kathleen Ruchalski; I Peter Shintaku; Phillip J Sanchez; Cristina Puig-Saus; Grace Cherry; Elizabeth Seja; Xiangju Kong; Jia Pang; Beata Berent-Maoz; Begoña Comin-Anduix; Thomas G Graeber; Paul C Tumeh; Ton N M Schumacher; Roger S Lo; Antoni Ribas
Journal:  N Engl J Med       Date:  2016-07-13       Impact factor: 91.245

2.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

3.  A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Achim Rothe; Stephanie Sasse; Max S Topp; Dennis A Eichenauer; Horst Hummel; Katrin S Reiners; Markus Dietlein; Georg Kuhnert; Joerg Kessler; Carolin Buerkle; Miroslav Ravic; Stefan Knackmuss; Jens-Peter Marschner; Elke Pogge von Strandmann; Peter Borchmann; Andreas Engert
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

4.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

Review 6.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

7.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

8.  HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Authors:  Marcel Nijland; Rianne N Veenstra; Lydia Visser; Chuanhui Xu; Kushi Kushekhar; Gustaaf W van Imhoff; Philip M Kluin; Anke van den Berg; Arjan Diepstra
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

9.  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Authors:  Christopher D Carey; Daniel Gusenleitner; Mikel Lipschitz; Margaretha G M Roemer; Edward C Stack; Evisa Gjini; Xihao Hu; Robert Redd; Gordon J Freeman; Donna Neuberg; F Stephen Hodi; Xiaole Shirley Liu; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2017-09-11       Impact factor: 22.113

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316

View more
  9 in total

Review 1.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

2.  Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment.

Authors:  Esther E E Drees; Yvonne W S Jauw; Erik van Dijk; Sven Borchmann; Sandra A W M Verkuijlen; Phylicia Stathi; Nils J Groenewegen; Nathalie J Hijmering; Daniella R A I Berry; Eric J Meershoek; Danielle Hoogmoed; Anne Kwakman; Tessa J Molenaar; Dirk M Pegtel; Bauke Ylstra; Daphne de Jong; Josée M Zijlstra; Margaretha G M Roemer
Journal:  Hemasphere       Date:  2022-07-04

3.  Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.

Authors:  Stephanie Sasse; Katharina Reddemann; Arjan Diepstra; Sven Borchmann; Ilske Oschlies; Antje Schnitter; Andreas Engert; Peter Borchmann; Wolfram Klapper
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

4.  Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.

Authors:  Joseph G Taylor; Andrew Clear; Maria Calaminici; John G Gribben
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

5.  PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.

Authors:  Philippe Armand; Yi-Bin Chen; Robert A Redd; Robin M Joyce; Jad Bsat; Erin Jeter; Reid W Merryman; Kimberly C Coleman; Parastoo B Dahi; Yago Nieto; Ann S LaCasce; David C Fisher; Samuel Y Ng; Oreofe O Odejide; Arnold S Freedman; Austin I Kim; Jennifer L Crombie; Caron A Jacobson; Eric D Jacobsen; Jeffrey L Wong; Sanjay S Patel; Jerome Ritz; Scott J Rodig; Margaret A Shipp; Alex F Herrera
Journal:  Blood       Date:  2019-04-05       Impact factor: 25.476

Review 6.  Acquired Resistance to Immune Checkpoint Blockade Therapies.

Authors:  Xianda Zhao; Dechen Wangmo; Matthew Robertson; Subbaya Subramanian
Journal:  Cancers (Basel)       Date:  2020-05-05       Impact factor: 6.639

Review 7.  Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth.

Authors:  Lutz Menzel; Uta E Höpken; Armin Rehm
Journal:  Front Immunol       Date:  2020-12-03       Impact factor: 7.561

8.  Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.

Authors:  Tomohiro Aoki; Lauren C Chong; Katsuyoshi Takata; Katy Milne; Ashley Marshall; Elizabeth A Chavez; Tomoko Miyata-Takata; Susana Ben-Neriah; Doria Unrau; Adele Telenius; Merrill Boyle; Andrew P Weng; Kerry J Savage; David W Scott; Pedro Farinha; Sohrab P Shah; Brad H Nelson; Christian Steidl
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-12       Impact factor: 11.205

Review 9.  Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review.

Authors:  Yujie Zhang; Zhichao Xing; Li Mi; Zhihui Li; Jingqiang Zhu; Tao Wei; Wenshuang Wu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.